• If you are trying to work out whether Caris Life Sciences at around US$19.84 is attractively priced or not, you will want a clear view of what that tag really reflects.
• The stock has recently shown mixed momentum, with a 4.4% return over the last 7 days and 5.8% over the last month, while the year to date return stands at a 26.5% decline.
• Recent headlines around Caris Life Sciences have focused on its role in precision medicine and diagnostics, alongside ongoing attention to how it funds and scales its research pipeline. Together, these themes can influence how investors think about both its risk profile and its long term potential.
• Right now, Caris Life Sciences has a valuation score of 3/6. The sections that follow break down how different valuation approaches arrive at that score, then finish with a broader framework that can help you judge the stock's value more confidently.

Approach 1: Caris Life Sciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those projections back to today, aiming to translate long term cash flows into a single present value per share.

For Caris Life Sciences, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $58.2 million. Analyst and extrapolated projections point to free cash flow of $416.15 million by 2030, with a series of annual estimates in between, such as around $97.0 million in 2026 and $173.6 million in 2027. Projections beyond the analyst horizon are extrapolated by Simply Wall St using its own growth assumptions.

Bringing all of those forecast cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $39.99 per share. Compared with a recent share price around $19.84, this implies the stock is 50.4% undervalued under these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Caris Life Sciences is undervalued by 50.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Caris Life Sciences Price vs Sales

For companies where earnings are not the main focus, the P/S ratio is a useful way to judge what investors are paying for each dollar of revenue. It helps you compare stocks even when profits are uneven, as long as you keep growth expectations and risk in mind.

Higher anticipated growth or lower perceived risk can justify a higher P/S ratio, while slower growth or higher risk usually calls for a lower one. Caris Life Sciences currently trades on a P/S of 6.91x, compared with the Biotechs industry average of 10.93x and a peer average of 4.72x.

Simply Wall St’s Fair Ratio for Caris Life Sciences is 6.16x. This is a proprietary estimate of what a reasonable P/S might look like after factoring in the company’s growth profile, profit margins, risk characteristics, market cap and its Biotechs industry context. That makes it more tailored than a simple comparison with peers or the broad industry, which ignore some of these details.

Set against the current 6.91x, the Fair Ratio of 6.16x suggests Caris Life Sciences is modestly overvalued on a sales basis under these assumptions.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Caris Life Sciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Simply Wall St’s Narratives let you attach a clear story to your numbers, linking your view on Caris Life Sciences’ revenue, earnings and margins to a forecast and Fair Value. You can then compare that Fair Value with the current share price to help you decide whether to buy, hold or sell. This all happens within an easy tool on the Community page that automatically refreshes when new earnings or news arrive. For example, one investor might build a bullish Caris narrative around a Fair Value of about US$74.17 that leans on its “Big Data” potential. Another might anchor on a more cautious Fair Value near US$26.23 that reflects concerns about margins and execution. Both of those perspectives can sit side by side for you to compare.

Do you think there's more to the story for Caris Life Sciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.